Other therapeutic monoclonal antibodies are directed at proinflammatory cytokines (IL-6, IL-1β, TNF and GM-CSF) to mitigate cytokine storm syndrome (CSS) that is the frequent cause of fatal acute respiratory distress syndromes (ARDS) in COVID-19 patients [47]. This evidence concerns the gene TNF and acute respiratory distress syndrome.